reports
BlackLine Announces Fourth Quarter and Full Year 2025 Financial Result...
BlackLine Announces Fourth Quarter and Full Year 2025 Financial Results LOS ANGELES, Feb. 10, 2026 (GLOBE NEWSWIRE) -- . (Nasdaq: BL), today announced financial results for the fourth quarter and full year ended December 31, 2025. “Our fourth-quarter performance, highlighted by record bookings, provides encouraging validation of the strategic transformation we initiated over two years ago,” said Owen Ryan, CEO of BlackLine. “The intentional steps we have taken to modernize our Go-To-Market engine, scale our Studio360 platform, and launch Verity AI to deliver outcomes for customers are tr...
BlackLine Confirms Receipt of Director Nominations
BlackLine Confirms Receipt of Director Nominations No Stockholder Action Required at This Time LOS ANGELES, Feb. 02, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BL) (“BlackLine” or the “Company”) today confirmed that Engaged Capital has submitted to the Company a notice of nomination of three director candidates to stand for election to the BlackLine Board of Directors at the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The date for the Annual Meeting has not yet been announced. The Nominating and Corporate Governance Committee of BlackLine’s Board of Directors will rev...
BlackLine Announces Date for Fourth Quarter and Full Year 2025 Earning...
BlackLine Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call LOS ANGELES, Jan. 27, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BL) announced today that it will release financial results for the fourth quarter and full year ended December 31, 2025 after market close on Tuesday, February 10, 2026 followed by a conference call hosted by management at 2:00 p.m. PT / 5:00 p.m. ET. A live webcast and replay will be accessible on BlackLine’s investor relations website at . To access the conference call by phone, please register , and dial-in details will be provided...
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study...
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data Precise MRD™ to transition from research-use-only into a limited clinical launch in March 2026 SALT LAKE CITY, Jan. 27, 2026 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a commercialization roadmap for its Precise MRD™ (molecular residual disease) assay and highlighted compelling data that reinforces the clinical value of ultrasensitive circulating tumor DNA (ctDNA) detection across cancer types. Myriad will launch Precise MRD with select...
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Y...
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance SALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2025, and provided full year 2026 financial guidance. These preliminary results will be included in a presentation that will be made available through a live webcast in the investor relations section of the ...
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Confe...
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference SALT LAKE CITY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Sam Raha, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, at 5:15 pm PT (8:15 pm ET). The presentation will be available through a live webcast and archived at . About Myriad Genetics Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated t...
BlackLine Board Member Tom Unterman Announces Intention to Retire
BlackLine Board Member Tom Unterman Announces Intention to Retire LOS ANGELES, Dec. 22, 2025 (GLOBE NEWSWIRE) -- BlackLine (Nasdaq: BL) (“BlackLine” or the “Company”) today announced that Tom Unterman has informed the Company that he intends to retire and will not stand for re-election to the BlackLine Board of Directors at the Company’s next Annual Meeting of Stockholders in May 2026. Mr. Unterman has served on the Board since 2010, providing invaluable guidance and strategic oversight during his tenure. “On behalf of the entire Board, I want to thank Tom for his many years of dedicated...
BlackLine Acquires WiseLayer to Enhance its AI Capabilities
BlackLine Acquires WiseLayer to Enhance its AI Capabilities Acquisition Accelerates BlackLine's Vision for an AI-Powered Finance and Accounting Platform LOS ANGELES, Dec. 15, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BL), the future-ready platform for the Office of the CFO, today announced it has acquired WiseLayer, a New York-based company that has pioneered a digital workforce of AI-powered agents to automate complex, judgment-based finance and accounting processes. Terms of the deal were not disclosed. This acquisition takes BlackLine’s industry-leading automation to the next level, empowe...
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at ...
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium New data will be presented about Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will present new data in eight abstracts at the ® (SABCS). The company will share the latest advances in the that support guideline-driven treatment decisions. Additionally, the company is presenting data on its , an ul...
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI ...
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health Actionable offering helps enable earlier, more personalized breast cancer interventions BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), and , today announced a joint collaboration in an effort to identify more women at high risk for breast cancer, with the goal of addressing a critical gap in breast cancer risk assessment without creating additional administrative burdens. The agreement brings together three leader...
BlackLine Issues Statement Regarding Shareholder Engagement
BlackLine Issues Statement Regarding Shareholder Engagement LOS ANGELES, Nov. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BL) (“BlackLine” or the “Company”) today issued the following statement: The Company and members of the Board of Directors actively meet with company stockholders on a regular basis. More recently, these meetings have included Engaged Capital with whom management and independent directors have met seven times in the past 12 months, including times when Engaged was and was not an investor in the Company. The Company remains open to constructive conversation with all stockho...
Myriad Genetics to Participate in Upcoming Investor Healthcare Confere...
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences SALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The 7th Annual Wolfe Research Healthcare Conference with a fireside chat on Tuesday, Nov. 18, 2025, at 1:20 pm ET.The 37th Annual Piper Sandler Healthcare Conference with a fireside chat on Tuesday, Dec. 2, 2025, at 12:00 pm ET. The presentations will be available through live audio webcas...
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Heredit...
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs 100% of genes strongly recommended by national oncology guidelines are included in the MyRisk Test SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced —the gold standard in germline testing—has been expanded to include genes referenced in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)1 and guidelines from American Society of Clinical Oncology (ASCO). The...
BlackLine Announces Third Quarter Financial Results
BlackLine Announces Third Quarter Financial Results LOS ANGELES, Nov. 06, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: BL), today announced financial results for the third quarter ended September 30, 2025. “BlackLine’s third-quarter results, with increasing revenue growth, solid margins, and strong free cash flow, demonstrate that our focus on improved execution is taking hold,” said Owen Ryan, CEO of BlackLine. “The deliberate changes we've made with our processes, technology, and people across our Product, Go-To-Market, and Operations teams are beginning to deliver the results we expect. As we ...
Myriad Genetics to Highlight Genetic Testing Advancements at 2025 Nati...
Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and reproductive genetic testing at the National Society of Genetic Counselors (NSGC) 44th Annual Conference. Myriad’s MyRisk® Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel® Prenatal Screen and Foresight® Carrier Screen are among ...
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterat...
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution Highlights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management expectations.Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively. Third quarter 2025 gross margin was 69.9%. Third quarter 2025 GAAP net loss of $27.4 million, or $0.29 per share, while adjusted EPS was $0.00. Th...
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to Ge...
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner Faster initial remission and response, persistent benefit over six months SALT LAKE CITY, Oct. 31, 2025 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in Mental Health Care (PRIME) study showed that treatment informed by the GeneSight® test led to faster initial remission and response in patients with Major Depressive Disord...
Myriad Genetics to Release Third Quarter 2025 Financial Results on Nov...
Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025 SALT LAKE CITY, Oct. 27, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2025 earnings conference call at 4:30 pm ET on Monday, Nov. 3, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the third quarter 2025. A live webcast of the conference call can be a...
BlackLine Announces Date for Third Quarter 2025 Earnings Release and C...
BlackLine Announces Date for Third Quarter 2025 Earnings Release and Conference Call LOS ANGELES, Oct. 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BL) announced today that it will release financial results for the third quarter ended September 30, 2025 after market close on Thursday, November 6, 2025 followed by a conference call hosted by management at 2:00 p.m. PT / 5:00 p.m. ET. A live webcast and replay will be accessible on BlackLine’s investor relations website at . To access the conference call by phone, please register , and dial-in details will be provided. To avoid delays, we encoura...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.